Back to RENAISSANCE TECHNOLOGIES LLC RENAISSANCE TECHNOLOGIES LLC

COLLCOLL
27 quarters

Position history for RENAISSANCE TECHNOLOGIES LLCRENAISSANCE TECHNOLOGIES LLC's holdings in COLLEGIUM PHARMACEUTICAL INC

RENAISSANCE TECHNOLOGIES LLC holds 1.4M shares of COLL (COLLEGIUM PHARMACEUTICAL INC), worth $49.5M as of 2026-Q2. The position was decreased (-7.0% shares). COLL represents 0.1% of RENAISSANCE TECHNOLOGIES LLC's portfolio.

Current Value

$49.5M

Current Shares

1.4M

Total Value Change

+$23.7M

Total Shares Change

+114,221

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
1.4M
-7.0%
$49.5M0.1%$36.20
0
2026-Q1
Decreased
1.5M
-9.1%
$48.6M0.1%$33.07
0
2025-Q4
Increased
1.6M
+1.1%
$74.9M0.1%$46.30
36
2025-Q3
Increased
1.6M
+5.1%
$56M0.1%$34.99
31
2025-Q2
Decreased
1.5M
-5.9%
$45M0.1%$29.57
0
2025-Q1
Decreased
1.6M
-2.7%
$48.2M0.1%$29.85
0
2024-Q4
Increased
1.7M
+0.3%
$47.6M0.1%$28.65
29
2024-Q3
Increased
1.7M
+8.1%
$64M0.1%$38.64
32
2024-Q2
Increased
1.5M
+8.0%
$49.3M0.1%$32.20
32
2024-Q1
Increased
1.4M
+2.4%
$55.1M0.1%$38.82
30
2023-Q4
Increased
1.4M
+18.1%
$42.6M0.1%$30.78
34
2023-Q3
Decreased
1.2M
-8.0%
$26.2M0.0%$22.35
0
2023-Q2
Increased
1.3M
+5.5%
$27.4M0.0%$21.49
30
2023-Q1
Increased
1.2M
+4.7%
$29M0.0%$23.99
30
2022-Q4
Decreased
1.2M
-7.0%
$26.8M0.0%$23.20
0
2022-Q3
Decreased
1.2M
-11.2%
$19.9M0.0%$16.02
0
2022-Q2
Increased
1.4M
+10.0%
$24.8M0.0%$17.72
32
2022-Q1
Increased
1.3M
+1.1%
$25.9M0.0%$20.36
29
2021-Q4
Decreased
1.3M
-3.7%
$23.5M0.0%$18.68
0
2021-Q3
Increased
1.3M
+4.4%
$25.8M0.0%$19.74
30
2021-Q2
Decreased
1.2M
-1.3%
$29.5M0.0%$23.64
0
2021-Q1
Decreased
1.3M
-8.5%
$30M0.0%$23.70
0
2020-Q4
Decreased
1.4M
-3.3%
$27.7M0.0%$20.03
0
2020-Q3
Decreased
1.4M
-12.1%
$29.8M0.0%$20.82
0
2020-Q2
Increased
1.6M
+2.6%
$28.5M0.0%$17.50
29
2020-Q1
Increased
1.6M
+26.7%
$25.9M0.0%$16.33
35
2019-Q4
New
1.3M
-
$25.8M0.0%$20.58
40

Other major holders of COLL: BNP PARIBAS FINANCIAL MARKETS, BlackRock, Inc., BlackRock Finance, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used